RhumbLine Advisers’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q3 | – | Sell |
-34,293
| Closed | -$514K | – | 2976 |
|
|
2016
Q2 | $514K | Buy |
34,293
+7,268
| +27% | +$93.4K | ﹤0.01% | 2179 |
|
|
2016
Q1 | $329K | Buy |
27,025
+660
| +3% | +$9.26K | ﹤0.01% | 2484 |
|
|
2015
Q4 | $419K | Buy |
26,365
+2,820
| +12% | +$44.4K | ﹤0.01% | 2361 |
|
|
2015
Q3 | $361K | Buy |
23,545
+936
| +4% | +$20.2K | ﹤0.01% | 2436 |
|
|
2015
Q2 | $550K | Sell |
22,609
-2,365
| -9% | -$56.7K | ﹤0.01% | 2262 |
|
|
2015
Q1 | $581K | Buy |
24,974
+3,050
| +14% | +$80.7K | ﹤0.01% | 2208 |
|
|
2014
Q4 | $551K | Sell |
21,924
-125
| -0.6% | -$3.67K | ﹤0.01% | 2218 |
|
|
2014
Q3 | $686K | Buy |
22,049
+250
| +1% | +$6.77K | ﹤0.01% | 2017 |
|
|
2014
Q2 | $564K | Buy |
21,799
+8,018
| +58% | +$178K | ﹤0.01% | 2196 |
|
|
2014
Q1 | $322K | Sell |
13,781
-810
| -6% | -$17.7K | ﹤0.01% | 2498 |
|
|
2013
Q4 | $370K | Buy |
14,591
+100
| +0.7% | +$2.26K | ﹤0.01% | 2439 |
|
|
2013
Q3 | $296K | Sell |
14,491
-143
| -1% | -$3.18K | ﹤0.01% | 2533 |
|
|
2013
Q2 | $307K | Buy |
+14,634
| New | +$262K | ﹤0.01% | 2622 |
|
RhumbLine Advisers's SGNT Position: Q3 2016 in Review
RhumbLine Advisers sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q3 2016, closing a stake of 34,293 shares — an estimated $514K sold.
RhumbLine Advisers first reported a position in SGNT in Q2 2013 and held it in 13 quarters. The position peaked at $686K in Q3 2014. 0 funds tracked by Wall St. Rank hold SGNT as of Q3 2016.
- RhumbLine Advisers reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q3 2016 after selling out during the quarter.
- RhumbLine Advisers sold 34,293 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q3 2016, an estimated $514K.
- RhumbLine Advisers first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2013 and held it in 13 quarters.
- RhumbLine Advisers's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $686K in Q3 2014.
- 0 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q3 2016.
Based on RhumbLine Advisers's 13F filing for Q3 2016, filed 8 Nov 2016.